Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1425Carcinoma, Renal Cell 586Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 123Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 77Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 50Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 43Neuroblastoma 39Uterine Cervical Neoplasms 38Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Head and Neck Neoplasms 26Clear-cell metastatic renal cell carcinoma 26

Interventions

tempol 1TEMPOL-H 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostate Cancer Recurrent × Genitourinary × Clear all
NCT04114825 2021-09-28

BRaVac

RhoVac APS

Phase 2 Active not recruiting
180 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡